Q2 2022 EPS Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP) Cut by SVB Leerink

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) – Analysts at SVB Leerink dropped their Q2 2022 earnings per share estimates for CRISPR Therapeutics in a report issued on Monday, May 9th. SVB Leerink analyst R. Bienkowski now forecasts that the company will post earnings of ($2.22) per share for the quarter, down from their previous estimate of ($1.76). SVB Leerink has a “Outperform” rating and a $120.00 price target on the stock. SVB Leerink also issued estimates for CRISPR Therapeutics’ Q3 2022 earnings at ($2.21) EPS, Q4 2022 earnings at ($2.26) EPS, FY2022 earnings at ($9.16) EPS and FY2023 earnings at ($8.94) EPS.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its quarterly earnings results on Monday, May 9th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by ($0.38). CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The firm had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.45 million. During the same period in the prior year, the firm posted ($1.51) earnings per share. CRISPR Therapeutics’s revenue for the quarter was up 74.4% compared to the same quarter last year.

CRSP has been the topic of several other reports. Brookline Capital Acquisition began coverage on CRISPR Therapeutics in a research note on Monday, February 14th. They issued a “buy” rating and a $143.00 price objective on the stock. Credit Suisse Group began coverage on CRISPR Therapeutics in a research report on Thursday, April 28th. They issued a “neutral” rating and a $78.00 price objective for the company. Chardan Capital reduced their price target on CRISPR Therapeutics from $171.00 to $168.00 in a research report on Tuesday. Truist Financial reiterated a “buy” rating and set a $220.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 16th. Finally, Stifel Nicolaus reduced their target price on CRISPR Therapeutics to $64.00 in a report on Wednesday, February 16th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $122.33.

Shares of CRISPR Therapeutics stock opened at $52.23 on Thursday. The firm has a market capitalization of $4.05 billion, a P/E ratio of 14.52 and a beta of 2.05. The firm’s 50 day moving average is $59.37 and its two-hundred day moving average is $68.35. CRISPR Therapeutics has a 52 week low of $42.51 and a 52 week high of $169.76.

Hedge funds have recently added to or reduced their stakes in the stock. Capital Impact Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter worth $26,000. Elkhorn Partners Limited Partnership raised its position in shares of CRISPR Therapeutics by 180.0% during the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock valued at $27,000 after acquiring an additional 225 shares in the last quarter. Kistler Tiffany Companies LLC increased its position in CRISPR Therapeutics by 6,250.0% in the fourth quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock worth $29,000 after buying an additional 375 shares during the period. CI Investments Inc. acquired a new position in shares of CRISPR Therapeutics during the third quarter valued at $30,000. Finally, IronBridge Private Wealth LLC bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $30,000. Hedge funds and other institutional investors own 56.12% of the company’s stock.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles